NIH-funded research Sbir 1 grant

Creating a skin patch to relieve nausea and vomiting during pregnancy

Official title: Development of an Ondansetron Transdermal Patch for Pregnancy-Induced Nausea and Vomiting

Funded at Integurx Therapeutics LLC · NIH-11008000 · Data updated 2026-11-12

This study is working on a new skin patch that delivers ondansetron to help pregnant people who are dealing with nausea and vomiting, making it easier for them to get relief without having to take pills.

More Pregnancy research and trials

Quick facts

Grant typeSbir 1 grant
Study typeNIH-funded research
Funding institutionIntegurx Therapeutics LLC
NIH-funded
Lab location1 site (Califon, United States)
Project startSeptember 1, 2024
Project endAugust 31, 2025
Funding year2024
Award (this year)$333,284
NIH project number1R43HD116663-01
Project IDNIH-11008000 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are pregnant individuals experiencing nausea and vomiting, particularly during the first and early second trimesters.

Less likely to help

Patients who are not pregnant or those who do not experience nausea and vomiting during pregnancy may not benefit from this research.

What this research studies

This research focuses on developing a transdermal patch that delivers ondansetron, a medication used to treat pregnancy-induced nausea and vomiting (PINV). The patch is designed to be applied once or twice a week, providing a continuous release of the medication without the need for oral ingestion, which can be difficult for those experiencing severe nausea. The project aims to enhance the absorption of ondansetron through the skin significantly, making it a more effective treatment option for pregnant individuals suffering from PINV. The research has already received guidance from the FDA on the regulatory approval process, indicating a clear path forward for the product's development.

Why it matters

Potential benefit: If successful, this research could provide a more convenient and effective treatment option for pregnant individuals suffering from debilitating nausea and vomiting.

How similar studies have gone: While there are existing treatments for PINV, the transdermal delivery method being explored in this research is novel and has not been widely tested in this context.

Where this research is happening

  • Integurx Therapeutics LLC
    Califon, United States
    Active

Researchers

  • Principal investigator: Shangold, Gary — Integurx Therapeutics LLC
  • Study coordinator: Shangold, Gary

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.